Convalescent plasma

Phase of research

Emergency use authorization

How it helps

Antiviral

Drug status

Experimental

37
Supporting references
6
Contradictory references
154
Clinical trials

General information

Convalescent plasma for COVID-19 treatment is the liquid phase of blood from donors who have recovered from the viral infection. It contains antibodies against SARS-CoV-2 factors and thus may help the recovery of newly infected patients (FDA).

On August 23, 2020, the FDA issued Emergency Use Authorization for convalescent plasma as potential promising COVID–19 treatment.


Supporting references

Link Tested on Impact factor Notes Publication date DB entry date
A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm
Severe severity Randomized controlled single-blind trial Mixed substance
Severe COVID-19 patients 2.32

Convalescent plasma administration was associated with improvement in clinical status and markers of cytokine storm in severe COVID-19 patients. This improvement did not translate into reduction of mortality in the treated patients compared to standard of care-only control group, however. Sample size: 30 + 30 control. Dosage: A 500 ml infusion. Primary outcome: Improvement in cytokine storm indicators.



Apr/10/2021 May/02/2021
Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products
Case series Mixed substance
B-cell depleted COVID-19 patients 3.37

In B-cell depleted COVID-19 patients due to anti-CD20 therapy, convalescent plasma administration was safe and led to viral clearance, clinical and laboratory improvement, even when administered more than 72 hours after symptoms' onset. Sample size: 7. Dosage inforamtion: Anti-Spike IgG titres of 1:100 or higher.

Apr/07/2021 May/02/2021
Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19
Case series Mixed substance
Immunosuppressed patients N/A (new)

The clinical improvement observed in the majority of the patients and development of detectable antibody responses after the last transfusion suggest that convalescent plasma might be considered as an early treatment option in immunosuppressed patients, with antibody levels after transfusion serving as a predictive marker for treatment success. Sample size: 14. Dosage: 1 (1 case) to 3 (11 cases) transfusions of 200 mL; PRNT50 of 40+.


Apr/01/2021 Apr/24/2021
Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma
In vitro Mixed substance Cohort study
Sera of convalescent COVID-19 individuals; Vero E6 cells; SARS-CoV-2 live virus (various isolates, including B.1.351) 42.78

The sera from COVID-19 convalescent individuals previously infected with SARS-CoV-2 B.1.351 variant were able to neutralize the viral infection by the same variant in vitro. The reduction of neutralizing capacity of these sera against strains that preceded B.1.351 was only 2.3-fold. On the contrary, the neutralization of the B.1.351 strain by sera of convalescent patients infected by the strains from the 1st infection wave declined significantly.

Mar/29/2021 Apr/08/2021
Convalescent plasma to treat COVID-19: clinical experience and efficacy
Severe severity Critical severity Mixed substance Cohort study
Severe to critical COVID-19 patients 4.83

Convalescent plasma administration was associated with clinical improvement and negative SARS-CoV-2 conversion. The administration of convalescent plasma with higher neutralizing antibody titres displayed higher efficacy. None of the patients in the treatment group died, which indicated lower mortality. Sample size: 19 + 43 control. Dosage: 4–5 ml/kg infusion(s).


Mar/18/2021 Mar/26/2021
Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19
Mixed substance Cohort study
Patients with haematological malignancies 3.82

Patients with haematological malignancies who were administered convalescent plasma 48–72 hours after SARS-CoV-2 infection diagnosis had significantly higher odds of survival and milder course of the infection. Sample size: 23 + 22 control. Dosage: At least one infusion of 200–250 mL.

Mar/08/2021 Apr/16/2021
Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques
Spike protein Protein factor Animal model In vitro Mixed substance
HEK293T cells; COVID-19 convalescent patient sera; immunized rhesus macaques' sera; SARS-CoV-2 variant Spike-pseudotyped virus 8.48

The sera from convalescent COVID-19 patients collected before D614G (SYSU-IHV), B.1.1.7, and 501Y.V2 strain emergence neutralized SARS-CoV-2 Spike-pseudotyped virus specific for all of the strains, but the neutralization capacity was significantly lower for the 501Y.V2 (“South Africa”) strain.

Feb/12/2021 Mar/01/2021
A Patient with X-Linked Agammaglobulinemia and COVID-19 Infection Treated with Remdesivir and Convalescent Plasma
Antibody Case report Mixed substance RdRpol Small molecule
An X-linked agammaglobulinemia patient. 6.78

Combined with remdesivir therapy. Observed clinical improvement in an X-linked agammaglobulinemia patient requiring ICU care, who did not respond to supportive care.

Feb/06/2021 Feb/19/2021
Neutralizing Activity to SARS‐CoV‐2 of Convalescent and Control Plasma Used in a Randomized Controlled Trial
In vitro Mixed substance
COVID-19 convalescent patient serum; in vitro immunochromatographic assay; 293T-ACE2 cells; SARS-CoV-2 Spike (truncated) pseudovirus 2.80

The convalescent plasma from all randomly selected donors had neutralizing anti-nucleocapsid protein (SARS-CoV-2) titres meeting FDA criteria. Cell pre-treatment with convalescent plasma led to significant inhibition of pseudovirus uptake.

Jan/15/2021 Jan/22/2021
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults
Elderly Randomized controlled double-blind trial Mild severity Mixed substance
Older patients 74.70

Significantly lower number (numerically 48% risk reduction) of older patients with mild COVID-19 who were treated with high-titre (anti-SARS-CoV-2 Spike antibody) convalescent plasma developed severe respiratory disease compared to placebo. Sample size: 80 + 80 placebo. Dosage: 250 mL with anti-Spike titres of more than 1:1000; administered less than 72 hours after symptom onset. Endpoint: Severe respiratory disease onset.



Jan/06/2021 Jan/17/2021
Safety and Efficacy of Convalescent Plasma for Severe COVID-19: Interim Report of a Multicenter Phase II Study from Saudi Arabia
Non-randomized controlled open trial Phase II clinical trial Mixed substance
Patients

Convalescent plasma administration was safe. Despite the lack of statistical significance, the authors of the study consider numerical decrease in mortality in the treatment group, compared to the control, sufficient to warrant further research of the potential of convalescent plasma treatment in COVID-19 patients. Sample size: 40 + 124 matched control. Dosage: One or more (up to five) infusions of 300 mL. IgG levels had to be detectable. Endpoints: Safety and the length of ICU stay (primary).



Dec/26/2020 Feb/03/2021
Effectiveness of Convalescent Plasma Therapy for COVID-19 Patients in Hunan, China
Severe severity Critical severity Case series Mixed substance
Patients 2.44

The therapy was generaly safe and led to clinical improvement. Sample size: 4 severe + 3 critical severity. Dosage: Neutralizing antibody titres of 1:320 to 1:1,280.


Dec/15/2020 Jan/16/2021
Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies
Cancer Case series Mild severity Mixed substance Moderate severity
B‐cell‐depleted patients with protracted COVID‐19 5.52

Convalescent plasma administration led to clinical improvement in 4 of the 5 patients with protracted COVID-19, impaired humoral immunity, and lacking neutralising antibodies. Dose specification: SARS-CoV-2 neutralising antibody titre of 1:160. Endpoint: Clinical response (temperature of <38°C, C‐reactive protein of <10 mg/l, and hospital discharge within 7 days).


Dec/13/2020 Dec/19/2020
Efficacy and safety of convalescent plasma therapy in severe COVID-19 patients with acute respiratory distress syndrome
ARDS Severe severity Mixed substance Cohort study
COVID-19 patients with mild to severe ARDS 3.94

A statistically significantly higher odds of recovery were observed in mild ARDS COVID-19 patients treated with convalescent plasma compared to control. Numerical difference was observed in moderate ARDS patients, as well. No difference was observed in the case of severe ARDS. The sample size was small, however. Sample size: 32 + 32 control. Dosage: An infusion of 600 ml of fresh ABO-identical and RhD-compatible convalescent plasma. Primary outcome: 28-day mortality.



Dec/02/2020 Feb/27/2021
Convalescent plasma therapy and remdesivir duo successfully salvaged an early liver transplant recipient with severe COVID-19 pneumonia
Severe severity Case report Mixed substance
A living donor liver transplant patient

In combination with remdesivir treatment, which was initiated earlier but did not lead to clinical improvement. After the third convalescent plasma infusion, clinical improvement (e. g. in hypoxia and inflammation) was observed in a living donor liver transplant patient who contracted severe COVID-19 during the third postoperative week. Dosage: 200 mL, 230 mL, and 200 mL on days 4,5, and 6 after fever onset, respectively. IgG titres of more than 1:1000.

Nov/30/2020 Dec/02/2020
"COVID-19 Convalescent Plasma Treatment of Moderate and Severe Cases of SARS-CoV-2 Infection: A Multicenter Interventional Study"
Severe severity Moderate severity Mixed substance Cohort study
Patients 3.20

Significantly higher rate of and shorter time to clinical improvement in moderate and severe COVID-19 patients. Improvement in oxygenation, lymphocyte counts, and CRP levels was detected, as well. Significantly reduced mortality was observed only in the moderate disease treatment group. Sample size: 135 + 233 control. Dosage: 79.3% of patients received 2 infusions of 200 mL 12 hours apart; 20.7% of patients received 1 infusion of 200-400 mL. Endpoint: Time to clinical improvement assessed on day 30 (primary).



Nov/26/2020 Dec/10/2020
Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy
Severe severity Case report Mixed substance
Patient with B cell alymphocytosis and hypogammaglobulinemia 6.78

Clinical improvement in a COVID-19 patient with severe hypogammaglobulinemia and absence of B cells (with Good syndrome) after administration of convalescent plasma (CP). The CP therapy was initiated on day 71 of symptomatic infection and no previous therapy provided any lasting significant clinical improvement. Dosage: 200 mL twice daily for two days (2 units with titer 1/160 and 2 with 1/40).

Nov/20/2020 Nov/30/2020
A patient affected by critical COVID-19 pneumonia, successfully treated with convalescent plasma
Critical severity Case report Mixed substance
Critical pneumonia patient with type 2 diabetes 1.29

Administration of COVID-19 convalescent plasma (together with hemoperfusion sessions and tocilizumab administration) might have contributed to clinical improvement of a 42-year old patient with type 2 diabetes diagnosed with critical COVID-19 pneumonia. Dosage: 2 infusions of 500 mL each.

Nov/05/2020 Nov/24/2020
Therapeutic Plasma Exchange followed by Convalescent Plasma transfusion in critical COVID-19- an exploratory study
Critical severity Mixed substance Cohort study
Invasive mechanical ventilation patients 3.20

Preceded by therapeutic plasma exchange. Clinical improvement in symptoms and inflammation markers. Invasive mechanical ventilation could be discontinued in majority of the cases. 28-day mortality was 28.6%. Sample size: 14. Dosage: 500 mL.

Nov/03/2020 Nov/12/2020
Significantly decreased mortality in a large cohort of COVID-19 patients transfused early with convalescent plasma containing high titer anti-SARS-CoV-2 spike protein IgG
Mixed substance Cohort study
Patients 3.49

Timely administration of convalescent plasma with high titres (≥1:1350) of antibodies targeting RBD of the SARS-CoV-2 spike protein significantly reduced adjusted 28-day mortality and unadjusted 60-day mortality. Sample size: 341 + 594 matched control. Dosage: Mostly single 300 mL transfusion with anti-RBD IgG titer mostly of ≥1:1350.


Nov/03/2020 Nov/12/2020
Safety and efficacy of COVID‐19 convalescent plasma in severe pulmonary disease: A report of 17 patients
Critical severity Case series Mixed substance
Patients 2.16

Improvement in clinical parameters (including oxygenation) in majority of the patients. Sample size: 17. Dosage: 1 unit of 200 mL; 2 units ca. 8 days apart in 3 patients. Antibody titres ranging from 1:400 to 1:6,400.

Oct/19/2020 Dec/31/2020
Hospitalized COVID-19 patients treated with convalescent plasma in a mid-size city in the Midwest
Severe severity Critical severity Mixed substance Cohort study
Patients 4.20

Early administration of convalescent plasma seems to reduce ventilatory requirements in severe to critical COVID-19 patients. Sample size: 31. Dosage: 250–300 mL.


Oct/12/2020 Jun/23/2020
Remdesivir failure with SARS-CoV-2 RNA-dependent RNA-polymerase mutation in a B-cell immunodeficient patient with protracted Covid-19
RdRpol Small molecule Case report Mixed substance
A post-rituximab B-cell immunodeficiency and persistent SARS-CoV-2 viremia patient. 8.31

Lead to reconvalescence, after a failed remdesivir treatment, of a patient infected by a SARS-CoV-2 strain with D484Y substitution in the RNA-dependent RNA polymerase with a a post-rituximab B-cell immunodeficiency and persistent SARS-CoV-2 viremia. Dosage: 4 times 200 mL within 4 days.

Sep/29/2020 Oct/24/2020
Successful recovery of COVID-19-associated recurrent diarrhea and gastrointestinal hemorrhage using convalescent plasma
Case report Mixed substance
Patients 2.33

Clinical improvement in 2 patients with recurrent gastrointestinal COVID-19-related symptoms. Sample size: 2. Dosage: 200-400 mL.

Sep/23/2020 Oct/16/2020
Convalescent plasma therapy for B-cell depleted patients with protracted COVID-19 disease
Case series Mixed substance
B-cell depleted patients with protracted COVID-19 17.54

Treatment resulted in decrease in body temperature, inflammation and the SARS-CoV-2 RNA levels.

Sep/21/2020 Oct/15/2020
Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study
Severe severity Critical severity Mixed substance Cohort study
Patients 30.64

Significantly reduced increase in supplemental oxygen requirement and increased rate of survival (for a 1:4 matched control; numerical for a 1:2 matched control). No severe transfusion-related adverse effect were noted. The receivers of convalescent plasma group were more frequently treated with anticoagulants than those in the control group. Sample size: 39 + 78 (1:2 matched control) + 156 (1:4 matched control). Dosage: 2 units of 250 ml (usually from the same donor); anti-spike IgG titers of ≥1:320 on the MSH-ELISA.


Sep/15/2020 Sep/20/2020
Treatment with convalescent plasma in solid organ transplant recipients with COVID‐19: Experience at large transplant center in New York City
Mixed substance Cohort study
Solid organ transplant recipients 1.67

Some solid organ transplant patients infected with SARS-CoV-2 may benefit from convalescent plasma treatment, especially in the case of early administration. Further verification is needed, however. Sample size: 13. Dosage: Two units of 500 mL total.

Sep/12/2020 Oct/04/2020
COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease
Children Case report Mixed substance
Infant patient 4.58

A 9-week-old female with trisomy 21 and a heart defect, non-responsive to remdesivir treatment, manifested clinical improvement after convalescent plasma transfusions. Dosage: 2 aliquots of CP (10 mL/kg per aliquot).

Sep/11/2020 Oct/04/2020
Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma
Severe severity Moderate severity Mixed substance Cohort study
Patients N/A (new)

Patients may benefit from treament with convalescent plasma with higher anti-S1 (SARS-CoV-2) levels. Sample size: 49. Dosage: 200 ml (additional 200 ml after 24 hrs if well-tolerated). Endpoint: Clinical improvement at day 14 (alive, not mechanically ventilated, recovered or mild to moderate COVID-19).



Sep/09/2020 Oct/05/2020
Convalescent plasma for pediatric patients with SARS‐CoV‐2‐associated acute respiratory distress syndrome
Children Critical severity Case series Mixed substance
Paediatric patients 2.36

Critically ill paediatric patients may benefit from convalescent plasma infusion. The treatment was not associated with elimination of endogenous antibody response or antibody-dependent enhancement. Donor plasma with higher antibody titres provided a more pronounced clinical improvement. Sample size: 4. Dosage: 2-4 mL/kg.

Sep/04/2020 Sep/29/2020
Patients with Prolonged Positivity of SARS-CoV-2 RNA Benefit from Convalescent Plasma Therapy: A Retrospective Study
Mixed substance Cohort study
Patients 3.24

In patients with prolonged positivity for the SARS-CoV-2 RNA, the convalescent plasma treatment may help eliminate virus and shorten the length of hospital stay. Sample size: 27. Dosage: 400 ml median total volume.

Aug/31/2020 Sep/23/2020
The therapeutic effectiveness of Convalescent plasma therapy on treating COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq
Severe severity Preprint Critical severity
Patients

reduced duration of infection and death rate

Jun/30/2020 Jun/30/2020
Early safety indicators of COVID-19 convalescent plasma in 5000 patients Patients 11.86

early indicators suggest that transfusion of convalescent plasma is safe in hospitalized patients with COVID-19

Jun/11/2020 May/15/2020
Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial
Severe severity Preprint
Patients

hyperimmune plasma (neutralizing antibodies titer ≥1:160)

May/29/2020 Jun/01/2020
Convalescent plasma treatment of severe COVID-19: A matched control study
Preprint
Patients

non-intubated patients may benefit more than those requiring mechanical ventilation

May/22/2020 May/25/2020
Treatment of COVID-19 Patients with Convalescent Plasma in Houston, Texas
Preprint
Patients

convalescent plasma obtained from donors with confirmed SARS-CoV-2 infection and had been symptom free for 14 days

May/13/2020 May/14/2020
[Potential antiviral therapeutics for 2019 Novel Coronavirus]. Similar viruses Feb/05/2020 Mar/30/2020

Contradictory references

Link Tested on Impact factor Notes Publication date DB entry date
Convalescent plasma treatment of critically ill intensive care COVID‐19 patients
Critical severity Mixed substance Cohort study
Critically ill COVID-19 ICU patients 2.80

The antibody titres in convalescent plasma were lower compared to the titres in the case of active critical infections; nevertheless, administration of convalescent plasma led to increase of the titres in the sera of critically ill ICU patients. The translation of this development into an improvement in clinical outcome was limited, however. Sample size: 8. Dosage: Three infusions of 200–280 ml, two days apart. Primary outcome: Humoral immune response.

Mar/30/2021 Apr/08/2021
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
Severe severity Randomized controlled double-blind trial Mixed substance
Severe COVID-19 pneumonia patients 74.70

No significant difference in the clinical outcomes between the treatment and the placebo group. Sample size: 228 + 105 placebo. Dosage: 500 mL (median) with median anti-SARS-CoV-2 antibody titre of 1:3200. Endpoints: Clinical status on an ordinal scale 30 days after the intervention (primary); clinical status on the ordinal scale at days 7 and 14,  the time to hospital discharge, the time to ICU discharge, the time to improvement in at least two categories on the ordinal scale, the time to death, and the time to recovery (secondary).



Nov/24/2020 Dec/01/2020
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
Randomized controlled open trial Mixed substance
Patients 27.60 (2018)

The use of convalescent plasma was not associated with reduction of primary outcome in moderate COVID-19 patients. Improvement was observed in some of the secondary outcomes (shortness of breath, fatigue, negative SARS-CoV-2 RNA conversion) at day 7. Sample size: 235 + 229 control. Dosage: Two doses of 200 mL 24 hours apart. Endpoint: Progression to severe disease or death within 28 days post-enrolment (primary).



Oct/26/2020 Oct/26/2020
Convalescent plasma for the treatment of patients with severe coronavirus disease 2019: A preliminary report
Critical severity Mixed substance Cohort study
Patients 2.02

Convalescent plasma administration in critically ill COVID-19 patients did not lead to a statistically significant improvement of respiratory status within 28 days, all-cause mortality at day 28 or viral clearance. Sample size: 40 + 40 control. Dosage: 400 mL AB0 compatible.
 

Sep/23/2020 Oct/16/2020
Convalescent plasma therapy in critically ill coronavirus disease 2019 patients with persistently positive nucleic acid test, case series report
Critical severity Case series Mixed substance
Critically ill patients with persistently positive nucleic acid tests 1.55

Late administration of convalescent plasma in critically ill COVID-19 patients has only limited benefits. Improvement in some clinical parameters was observed but overal outcome (mortality) was poor. Sample size: 5. Dosage: 400 mL (3 patients), 1,200 mL (2 patients) (Ab titer >1:640).

Sep/04/2020 Oct/02/2020
Convalescent Plasma for COVID-19. A randomized clinical trial Patients

no difference in mortality, hospital stay or day-15 disease severity in comparison to standard of care

Jul/03/2020 Jul/06/2020

Clinical trials

ID Title Status Phase Start date Completion date
NCT05077930 Convalescent Plasma Therapy for Hospitalized Patients With COVID-19 Recruiting Phase 2 Oct/01/2021 Jan/01/2022
NCT04644198 Convalescent Plasma Transfusion in Severe COVID-19 Patients in Jamaica Recruiting Phase 2 Jun/01/2021 Dec/01/2021
NCT04884477 COVID-19 Infection in Patients Receiving Anti-CD20 Therapy Active, not recruiting Jun/01/2021 Jun/30/2022
NCT04954937 Convalescent Plasma Donor Vaccine Study An Observational Antibody Level Study. Recruiting Apr/20/2021 Apr/20/2022
NCT04836260 Preemptive Use of Convalescent Plasma for High-risk Patients With COVID-19 Recruiting Phase 3 Apr/08/2021 Dec/31/2021
NCT04390503 Convalescent Plasma for Early Treatment of COVID-19 Recruiting Phase 2 Mar/12/2021 Apr/01/2022
NCT04769245 The Effectiveness of ACB-IP 1.0 Convalescent Plasma in COVID-19 Infection Recruiting Feb/18/2021 Jun/01/2021
NCT04730401 Convalescent Plasma in the Treatment of Covid-19 Recruiting Phase 2 Jan/27/2021 Dec/31/2021
NCT04712344 Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO) Recruiting Phase 2 Jan/18/2021 Sep/01/2021
NCT04681430 Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals Recruiting Phase 2 Jan/08/2021 Nov/01/2021
NCT04528368 Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory Support Recruiting Phase 2 Dec/11/2020 Jan/30/2022
NCT04649879 Convalescent Plasma for Treatment of COVID-19: An Open Randomised Controlled Trial Not yet recruiting Phase 2|Phase 3 Dec/03/2020 Feb/01/2022
NCT04642014 Application of Convalescent Plasma in the Treatment of SARS CoV-2 Disease (COVID-19) With Evaluation of Therapy Effectiveness Not yet recruiting Not Applicable Dec/01/2020 May/01/2022
NCT04873414 Convalescent Plasma as Adjunct Therapy for COVID-19 Recruiting Phase 2|Phase 3 Dec/01/2020 Dec/31/2021
NCT04521036 Convalescent Plasma for COVID-19 Patients (CPCP) Not yet recruiting Phase 1|Phase 2 Dec/01/2020 Oct/30/2021
NCT04669990 Remdesivir and Convalescent Plasma Therapy for Treatment of COVID-19 Infection in Nepal : A Registry Study Recruiting Nov/19/2020 Nov/19/2021
NCT04539275 COVID-19 (VA CURES-1) Completed Phase 3 Nov/16/2020 Sep/30/2021
NCT04634422 Plasma Exchange (PLEX) and Convalescent Plasma (CCP) in COVID-19 Patients With Multiorgan Failure Recruiting Not Applicable Nov/16/2020 Jun/30/2022
NCT04456413 Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection Recruiting Phase 2 Nov/06/2020 Nov/01/2021
NCT04764747 Effectiveness of Convalescent Plasma in Hospitalized Patients With COVID-19 Completed Nov/01/2020 Apr/25/2021
NCT04589949 Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study) Recruiting Phase 3 Oct/12/2020 Nov/01/2023
NCT04377568 Efficacy of Human Coronavirus-immune Convalescent Plasma for the Treatment of COVID-19 Disease in Hospitalized Children Withdrawn Phase 2 Oct/07/2020 May/01/2022
NCT04467151 Administration of Anti-SARS-CoV-2 Convalescent Plasma in Hospitalized, Non-ICU Patients With COVID-19 Withdrawn Phase 2 Oct/01/2020 Dec/01/2021
NCT04516811 Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19 Recruiting Phase 3 Sep/21/2020 Jul/31/2022
NCT04497324 PERUCONPLASMA: Evaluating the Use of Convalescent Plasma as Management of COVID-19 Recruiting Phase 2 Sep/21/2020 May/15/2021
NCT04567173 Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19 Recruiting Phase 2|Phase 3 Sep/21/2020 Jun/30/2021
NCT04372979 Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients. Recruiting Phase 3 Sep/14/2020 Jun/01/2021
NCT04395170 Convalescent Plasma (PC) and Human Intravenous Anti-COVID-19 Immunoglobulin (IV Anti COVID-19 IgG) in Patients Hospitalized for COVID-19. Not yet recruiting Phase 2|Phase 3 Sep/01/2020 Jun/01/2021
NCT04558476 Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation Recruiting Phase 2 Sep/01/2020 Sep/01/2022
NCT04433910 A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19 Completed Phase 2 Aug/30/2020 Feb/22/2021
NCT04388410 Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19 Recruiting Phase 2|Phase 3 Aug/25/2020 Dec/31/2020
NCT04513158 Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection Recruiting Phase 2 Aug/14/2020 Dec/31/2021
NCT04438057 Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19 Recruiting Phase 2 Aug/12/2020 Aug/12/2021
NCT04355767 Convalescent Plasma in Outpatients With COVID-19 Completed Phase 3 Aug/11/2020 Mar/29/2021
NCT04747158 COVID-19 Convalescent Plasma Therapy Completed Phase 2|Phase 3 Aug/10/2020 Jan/10/2021
NCT04432103 Treatment of Severe and Critical COVID-19 Pneumonia With Convalescent Plasma Terminated Phase 3 Aug/08/2020 Jan/29/2021
NCT04332835 Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study Completed Phase 2|Phase 3 Aug/08/2020 Nov/15/2020
NCT04480632 Therapeutic Plasmapheresis in Critically Ill Adult Patients With COVID-19 Confirmed Diagnosis Not yet recruiting Phase 2 Aug/01/2020 Aug/01/2022
NCT04516954 Convalescent Plasma for COVID-19 Patients Enrolling by invitation Early Phase 1 Aug/01/2020 Dec/30/2020
NCT04462848 Covid-19 Convalescent Plasma as Prevention and Treatment for Children With Underlying Medical Conditions Not yet recruiting Phase 1 Aug/01/2020 Dec/01/2024
NCT04570982 Clinical Protocol for Convalescent Plasma and Remdesivir Therapy in Nepal Recruiting Jul/30/2020 Dec/30/2020
NCT04460547 Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic Not yet recruiting Jul/25/2020 Sep/20/2020
NCT04973488 Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients Completed Phase 2|Phase 3 Jul/25/2020 Jan/10/2021
NCT04365439 Convalescent Plasma for COVID-19 Active, not recruiting Not Applicable Jul/20/2020 Jun/30/2021
NCT04547660 Convalescent Plasma for Severe COVID-19 Patients Completed Phase 3 Jul/16/2020 Jan/07/2021
NCT04432272 ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS) Completed Phase 2 Jul/16/2020 Nov/28/2020
NCT04716556 TranSfUsion of coNvalescent plAsma for the Early Treatment of pneuMonIa in COVID-19 Patients Completed Not Applicable Jul/16/2020 May/31/2021
NCT04408040 Use of Convalescent Plasma for COVID-19 Terminated Phase 2 Jul/14/2020 Sep/14/2021
NCT04497779 Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma Recruiting Jul/13/2020 Aug/21/2023
NCT04803370 Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma Recruiting Not Applicable Jul/08/2020 Sep/01/2021
NCT04463823 "NORPLASMA" Covid-19 Convalescent Plasma Treatment Monitoring Study Recruiting Jul/06/2020 May/31/2025
NCT04452812 Statistical and Epidemiological Study Based on the Use of Convalescent Plasma for the Management of Patients With COVID-19 Not yet recruiting Phase 1|Phase 2 Jul/06/2020 Apr/01/2021
NCT04458363 Convalescent Plasma in Pediatric COVID-19 Completed Early Phase 1 Jul/04/2020 Sep/01/2020
NCT04425837 Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19 Not yet recruiting Phase 2|Phase 3 Jul/01/2020 Feb/01/2021
NCT04555109 Convalescent Plasma for COVID-19 Research Donor Study Active, not recruiting Jun/30/2020 Oct/31/2022
NCT04353206 Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure Recruiting Early Phase 1 Jun/27/2020 May/01/2021
NCT04468009 Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma Completed Phase 2 Jun/25/2020 Jun/19/2021
NCT04418518 A Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness Recruiting Phase 3 Jun/24/2020 Dec/01/2021
NCT04542967 Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease Completed Phase 2 Jun/23/2020 Sep/30/2020
NCT04385186 Inactivated Convalescent Plasma as a Therapeutic Alternative in Patients CoViD-19 Not yet recruiting Phase 2 Jun/20/2020 Dec/30/2020
NCT04542941 Assessment of Safety and Efficacy of CCP Completed Not Applicable Jun/16/2020 Dec/31/2020
NCT04428021 Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure Active, not recruiting Phase 2 Jun/15/2020 Oct/31/2021
NCT04425915 Efficacy of Convalescent Plasma Therapy in Patients With COVID-19 Completed Phase 3 Jun/14/2020 Dec/15/2020
NCT04323800 Convalescent Plasma to Stem Coronavirus (CSSC-001) Active, not recruiting Phase 2 Jun/10/2020 Jan/01/2023
NCT04421404 Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients Completed Phase 2 Jun/09/2020 Apr/30/2021
NCT04502472 Open-label Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma Recruiting Phase 2|Phase 3 Jun/06/2020 Dec/31/2021
NCT04479163 Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2 Completed Not Applicable Jun/04/2020 Oct/25/2020
NCT04373460 Convalescent Plasma to Limit SARS-CoV-2 Associated Complications Active, not recruiting Phase 2 Jun/03/2020 Jan/31/2023
NCT04438694 Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection Recruiting Phase 1|Phase 2 Jun/01/2020 Dec/31/2021
NCT04391101 Convalescent Plasma for the Treatment of Severe SARS-CoV-2 (COVID-19) Not yet recruiting Phase 3 Jun/01/2020 Dec/01/2021
NCT04412486 COVID-19 Convalescent Plasma (CCP) Transfusion Recruiting Early Phase 1 Jun/01/2020 May/31/2022
NCT04383548 Clinical Study for Efficacy of Anti-Corona VS2 Immunoglobulins Prepared From COVID19 Convalescent Plasma Prepared by VIPS Mini-Pool IVIG Medical Devices in Prevention of SARS-CoV-2 Infection in High Risk Groups as Well as Treatment of Early Cases of COVID19 Patients Not yet recruiting Not Applicable Jun/01/2020 Jan/01/2021
NCT04415086 Treatment of Patients With COVID-19 With Convalescent Plasma Active, not recruiting Phase 2 Jun/01/2020 May/22/2022
NCT04377672 Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19) Active, not recruiting Phase 1 May/28/2020 Jul/01/2023
NCT04374526 Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression. Completed Phase 2|Phase 3 May/27/2020 May/26/2021
NCT04474340 COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients Recruiting Phase 1 May/21/2020 Dec/30/2020
NCT04403477 Convalescent Plasma Therapy in Severe COVID-19 Infection Recruiting Phase 2 May/20/2020 Oct/30/2020
NCT04405310 Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial Completed Phase 2 May/20/2020 Dec/10/2020
NCT04356482 CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19 Recruiting Phase 1|Phase 2 May/20/2020 Dec/01/2020
NCT04380935 Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome Recruiting Phase 2|Phase 3 May/18/2020 Oct/31/2020
NCT04383535 Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia Completed Not Applicable May/15/2020 Sep/27/2020
NCT04569188 Convalescent Plasma in COVID-19 Elderly Patients Completed Phase 2 May/15/2020 Sep/03/2020
NCT04397757 COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2. Completed Phase 1 May/13/2020 Mar/08/2021
NCT04354831 A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection Active, not recruiting Phase 2 May/11/2020 May/01/2023
NCT04374487 Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications Active, not recruiting Phase 2 May/09/2020 Aug/09/2021
NCT04333355 Safety in Convalescent Plasma Transfusion to COVID-19 Terminated Phase 1 May/08/2020 Aug/20/2020
NCT04384497 Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study Recruiting Phase 1|Phase 2 May/07/2020 Dec/01/2020
NCT04381858 Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia Completed Phase 3 May/06/2020 Nov/26/2020
NCT04374565 Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia Active, not recruiting Phase 2 May/05/2020 Apr/05/2021
NCT04442191 Convalescent Plasma as a Possible Treatment for COVID-19 Recruiting Phase 2 May/05/2020 May/05/2021
NCT04392232 A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection Recruiting Phase 2 May/05/2020 Dec/31/2020
NCT04385199 Convalescent Plasma for Patients With COVID-19 Completed Phase 2 May/04/2020 Aug/01/2020
NCT04375098 Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection Completed Phase 2 May/04/2020 Aug/17/2020
NCT04429854 Donated Antibodies Working Against nCoV Completed Phase 2 May/02/2020 Apr/30/2021
NCT04407208 Convalescent Plasma Therapy in Patients With COVID-19 Completed Phase 1 May/01/2020 Jun/22/2020
NCT04352751 Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020 Recruiting Not Applicable May/01/2020 Apr/01/2021
NCT04393727 Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19 Terminated Phase 2 May/01/2020 Sep/30/2020
NCT04565197 Convalescent Plasma Therapy for COVID-19 Patients Active, not recruiting Early Phase 1 May/01/2020 Dec/30/2020
NCT04332380 Convalescent Plasma for Patients With COVID-19: A Pilot Study Completed Phase 2 May/01/2020 Jul/28/2020
NCT04392414 Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease Completed Phase 2 May/01/2020 Sep/23/2020
NCT04545047 Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19 Active, not recruiting May/01/2020 Jun/30/2022
NCT04388527 COVID-19 Convalescent Plasma for Mechanically Ventilated Population Completed Phase 1 Apr/30/2020 Jan/30/2021
NCT04397523 Efficacy and Safety of COVID-19 Convalescent Plasma Completed Not Applicable Apr/30/2020 May/10/2021
NCT04471051 An Observational Cohort Trial of Outcomes and Antibody Responses Following Treatment With COVID19 Convalescent Plasma in Hospitalized COVID-19 Patients Completed Apr/30/2020 Aug/20/2020
NCT04361253 Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy Terminated Phase 3 Apr/30/2020 Jun/30/2021
NCT04869072 Convalescent Plasma Therapy - Zurich Protocol Completed Phase 1 Apr/29/2020 Mar/30/2021
NCT04434131 Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19 Recruiting Phase 2 Apr/28/2020 Apr/28/2025
NCT04358783 Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia Completed Phase 2 Apr/27/2020 May/01/2021
NCT04476888 Convalescent Plasma Treatment in COVID-19 Completed Not Applicable Apr/26/2020 Oct/10/2020
NCT04600440 Convalescent Plasma in the Treatment of Covid-19 Recruiting Not Applicable Apr/25/2020 Feb/28/2022
NCT04362176 Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults Recruiting Phase 3 Apr/24/2020 Sep/30/2021
NCT04816942 Clinical Efficacy of Early Administration of Convalescent Plasma Among COVID-19 Cases in Egypt Completed Phase 3 Apr/23/2020 Oct/12/2020
NCT04408209 Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection Recruiting Not Applicable Apr/23/2020 Sep/15/2021
NCT04359810 Plasma Therapy of COVID-19 in Severely Ill Patients Completed Phase 2 Apr/21/2020 Dec/30/2020
NCT04346446 Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients Completed Phase 2 Apr/20/2020 May/30/2020
NCT04356534 Convalescent Plasma Trial in COVID -19 Patients Completed Not Applicable Apr/19/2020 Jul/09/2020
NCT04347681 Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19 Recruiting Phase 2 Apr/18/2020 Apr/11/2021
NCT04535063 Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia Recruiting Phase 3 Apr/18/2020 Feb/25/2021
NCT04364737 CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients Active, not recruiting Phase 2 Apr/17/2020 Dec/31/2022
NCT04376034 Convalescent Plasma Collection and Treatment in Pediatrics and Adults Recruiting Phase 3 Apr/16/2020 Mar/30/2021
NCT04345991 Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort Completed Phase 2 Apr/15/2020 May/28/2021
NCT04389710 Convalescent Plasma for the Treatment of COVID-19 Completed Phase 2 Apr/15/2020 Dec/07/2020
NCT04345679 Anti COVID-19 Convalescent Plasma Therapy Recruiting Early Phase 1 Apr/14/2020 Sep/01/2021
NCT04357106 COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma Recruiting Phase 2 Apr/13/2020 Aug/01/2020
NCT04390178 Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19) Active, not recruiting Phase 1|Phase 2 Apr/10/2020 Dec/01/2020
NCT04340050 COVID-19 Convalescent Plasma Completed Early Phase 1 Apr/10/2020 Dec/23/2020
NCT04343261 Convalescent Plasma in the Treatment of COVID 19 Completed Phase 2 Apr/10/2020 Aug/13/2020
NCT04343755 Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection Active, not recruiting Phase 2 Apr/09/2020 Apr/01/2022
NCT04342182 Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study) Active, not recruiting Phase 2|Phase 3 Apr/08/2020 Jul/31/2021
NCT04344535 Convalescent Plasma vs. Standard Plasma for COVID-19 Terminated Phase 1|Phase 2 Apr/08/2020 Feb/01/2021
NCT04384588 COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID) Recruiting Phase 2|Phase 3 Apr/07/2020 Apr/06/2021
NCT04345523 Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients Completed Phase 2 Apr/03/2020 Apr/05/2021
NCT04441424 Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients Completed Not Applicable Apr/03/2020 Jun/01/2020
NCT04333251 Study Testing Convalescent Plasma vs Best Supportive Care Not yet recruiting Phase 1 Apr/01/2020 Dec/31/2022
NCT04325672 Convalescent Plasma to Limit Coronavirus Associated Complications Withdrawn Phase 2 Apr/01/2020 Dec/31/2022
NCT05046652 Effectiveness of Convalescent Plasma Therapy in 8 Non-Intubated COVID-19 Patients in Indonesia: A Case Series Completed Apr/01/2020 Dec/31/2020
NCT04492501 Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan Completed Not Applicable Apr/01/2020 Jul/20/2020
NCT04389944 Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19 Completed Not Applicable Mar/31/2020 Jun/30/2020
NCT04327349 Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial Enrolling by invitation Not Applicable Mar/28/2020 Sep/30/2020
NCT04554992 Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019) Active, not recruiting Phase 1 Mar/20/2020 Jun/01/2022
NCT04381936 Randomised Evaluation of COVID-19 Therapy Recruiting Phase 2|Phase 3 Mar/19/2020 Dec/01/2031
NCT04348656 CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1) Terminated Phase 3 Mar/14/2020 Jun/16/2021
NCT04292340 Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19 Recruiting Feb/01/2020 Dec/31/2020
NCT04616976 COVID-19 With Convalescent Plasma Completed Jan/01/2020 Nov/01/2020
NCT02735707 Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia Recruiting Phase 4 Apr/11/2016 Dec/01/2023
NCT04372368 Convalescent Plasma for the Treatment of Patients With COVID-19 No longer available Jan/01/1970 Jan/01/1970
NCT04445207 Experimental Expanded Access Treatment With Convalescent Plasma for the Treatment of Patients With COVID-19 Available Jan/01/1970 Jan/01/1970
NCT04363034 Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program Temporarily not available Jan/01/1970 Jan/01/1970
NCT04338360 Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19 Approved for marketing Jan/01/1970 Jan/01/1970
NCT04374370 SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP) No longer available Jan/01/1970 Jan/01/1970
NCT04420988 Investigational COVID-19 Convalescent Plasma Infusion for Severely or Life-threateningly Ill COVID-19 Patients Available Jan/01/1970 Jan/01/1970
NCT04360486 Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) Available Jan/01/1970 Jan/01/1970
NCT04358211 Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19 No longer available Jan/01/1970 Jan/01/1970
NCT04472572 Expanded Access to Convalescent Plasma for Treatment of COVID-19 Available Jan/01/1970 Jan/01/1970